AGN-232411

AGN-232411 is a small molecule drug that acts as an agonist of the formyl peptide receptor 1 (FPR1). It was initially developed by Allergan and is now being further developed by AbbVie and Allgenesis Biotherapeutics. The drug is formulated as a topical ophthalmic solution and has been investigated primarily for the treatment of dry eye syndromes, including keratoconjunctivitis sicca. Its mechanism of action involves activation of FPR1, which plays a role in modulating inflammation, making it relevant for ocular inflammatory conditions. Clinical trials have reached up to Phase 2 for dry eye syndromes, but there are no approvals or reported marketing authorizations to date[1][2][3][4].